Kazakhstan’s government has committed to providing HIV, TB and Hepatitis treatment free of charge for everyone in need. However, a lack of competition has paved the route for high prices – a key reason for the treatment gaps.
Our campaign partner in Kazakhstan, Answer, is focused on reducing the price of key medicines.
Progress to date includes:
Civil society, including Answer, were involved in negotiations that saw ViiV Healthcare reduce the price for dolutegravir (DTG). 1,576 patients, of the 11,000 receiving HIV treatment are accessing DTG-based regimens. Answer would like to see the price reduce further, and the number of people accessing DTG therefore increase (price information to follow).
Kazakhstan’s Hep C elimination programme started in 2018, which saw almost 19,000 patients treated in the same year.
Civil society has been actively involved in HIV and Hep C procurement and provision monitoring and advocacy. Sofosbuvir and daclatasvir has been available through the elimination programme. Largely thanks to the efforts of the civil society, the current price (generics procured through international agencies) is around $100 for a three-month course.
Answer’s priorities include:
Continuing to invest in strategies that reduce the price of optimal treatment regimens, and providing recommendations for treatment and procurement. This includes working on price reduction with pharmaceutical companies.
Directly challenging unmerited patents at all stages: Pre-patent, by ensuring the patent examination process is fit-for-purpose; opposing unmerited patents; and advocating to revoke patents that shouldn’t have been approved.
Continue to support the Hep C elimination program, collaborating with community and government.
Last updated February 2019.
Related news articles
MMA’s partners in Kazakhstan call for systemic changes to the country’s intellectual property and access to medicines framework in their annual report
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.